EXHIBIT 10(b)
================================================================================
LICENSE AGREEMENT
originally dated as of September 23, 1997
amended and restated in its entirety
as of February 22, 2002
by and between
ALLIANCE PHARMACEUTICAL CORP.
and
SCHERING AKTIENGESELLSCHAFT
================================================================================
TABLE OF CONTENTS
Page
ARTICLE I
DEFINITIONS
SECTION 1.01. Definitions...............................................1
ARTICLE II
DEVELOPMENT
SECTION 2.01. Development...............................................8
SECTION 2.02. Drug Approval Applications................................9
SECTION 2.03. Costs of Development......................................9
SECTION 2.04. Right to Engage Third Parties.............................9
SECTION 2.05. Schering Portfolio........................................9
ARTICLE III
LICENSES
SECTION 3.01. Patent License to Schering................................9
SECTION 3.02. Patent and Trademark License to Alliance.................10
SECTION 3.03. Third Party Technology...................................10
ARTICLE IV
COMMERCIALIZATION
SECTION 4.01. Marketing ...............................................11
SECTION 4.02. Tax Considerations.......................................11
ARTICLE V
ROYALTIES
SECTION 5.01. Schering Product Royalties...............................12
SECTION 5.02. Alliance Royalties.......................................14
SECTION 5.03. Royalty Reports and Payments.............................16
SECTION 5.04. Payments; Interest.......................................16
SECTION 5.05. Taxes....................................................16
SECTION 5.06. Payments to or Reports by Affiliates.....................16
SECTION 5.07. Payment Currency.........................................17
ARTICLE VI
MANUFACTURE AND SUPPLY
SECTION 6.01. Manufacture and Supply by Alliance.......................17
i
CONFIDENTIAL TREATMENT
SECTION 6.02. Regulatory Approval for Manufacturing....................17
SECTION 6.03. Step-in Right of Schering................................18
SECTION 6.04. Technology and Know-How Transfer.........................18
SECTION 6.05. Regulatory Approval......................................18
SECTION 6.06. DMF......................................................19
SECTION 6.07. Acceptance and Pricing...................................19
SECTION 6.08. Competitive Cost of Goods................................19
SECTION 6.09. Packaging................................................19
ARTICLE VII
CONFIDENTIALITY
SECTION 7.01. Confidentiality; Exceptions..............................20
SECTION 7.02. Authorized Disclosure....................................20
SECTION 7.03. Survival.................................................21
SECTION 7.04. Termination of Prior Agreement ..........................21
SECTION 7.05. Publications ............................................21
SECTION 7.06. Publicity Review.........................................21
ARTICLE VIII
OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS
SECTION 8.01. Ownership................................................22
SECTION 8.02. Patent Filings...........................................22
SECTION 8.03. Third Party Patent Rights................................22
SECTION 8.04. Enforcement Rights.......................................22
SECTION 8.05. Defense and Settlement of Third Party Claims.............23
SECTION 8.06. Patent Expenses..........................................23
SECTION 8.07. Trademarks...............................................23
ARTICLE IX
REPRESENTATIONS AND WARRANTIES
SECTION 9.01. Representations and Warranties...........................23
SECTION 9.02. Performance by Affiliates................................24
ARTICLE X
INFORMATION AND REPORTS
SECTION 10.01. Information and Reports During Development and
Commercialization .......................................24
SECTION 10.02. Adverse Drug Experiences.................................25
SECTION 10.03. Records of Revenues and Expenses.........................25
SECTION 10.04. Applicability............................................26
ii
CONFIDENTIAL TREATMENT
ARTICLE XI
TERM AND TERMINATION
SECTION 11.01. Term.....................................................27
SECTION 11.02. Termination..............................................27
SECTION 11.03. Surviving Rights.........................................29
ARTICLE XII
INDEMNIFICATION
SECTION 12.01. Indemnification .........................................29
ARTICLE XII
MISCELLANEOUS
SECTION 13.01. Assignment...............................................30
SECTION 13.02. Retained Rights..........................................30
SECTION 13.03. Force Majeure............................................30
SECTION 13.04. Further Actions..........................................31
SECTION 13.05. No Trademark Rights......................................31
SECTION 13.06. Notices..................................................31
SECTION 13.07. Waiver...................................................32
SECTION 13.08. Severability.............................................32
SECTION 13.09. Ambiguities..............................................32
SECTION 13.10. Governing Law............................................32
SECTION 13.11. Headings.................................................32
SECTION 13.12. Counterparts.............................................32
SECTION 13.13. Entire Agreement; Amendments.............................32
SECTION 13.14. Expenses.................................................33
SECTION 13.15. Independent Contractors..................................33
SECTION 13.16. Use of Names.............................................33
EXHIBITS
EXHIBIT A Determination of Certain Accounting Terms
EXHIBIT B Alliance Patents
EXHIBIT C Alliance HI Patents
EXHIBIT D Schering HI Patents
iii
LICENSE AGREEMENT (the "AGREEMENT") originally dated as of September 23,
1997 (the "EFFECTIVE DATE"), and amended and restated in its entirety as of
February 22, 2002 (the "RESTATEMENT DATE") by and between
ALLIANCE
PHARMACEUTICAL CORP., a
New York corporation having its principal place of
business at ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ (hereinafter
referred to as "ALLIANCE") and SCHERING AKTIENGESELLSCHAFT, a German corporation
having its principal place of business at ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ (hereinafter
referred to as "SCHERING"). Alliance and Schering are sometimes referred to
herein individually as a "Party" and collectively as the "Parties."
W I T N E S S E T H:
WHEREAS, Schering is a leading multinational health care company;
WHEREAS, Alliance is developing through its research and development
activities certain technology for use in ultrasound imaging techniques, and has
the right to grant rights and licenses and/or sublicenses under the Alliance
Patents (hereinafter defined) and Alliance Know-How (hereinafter defined);
WHEREAS, the Parties entered into a
License Agreement dated as of September
23, 1997, as amended by First Amendment to
License Agreement dated as of
December 30, 1998, Amendment No. 2 to the
License Agreement dated December
20/21, 2000, the side letter of December 20, 2000 and the Waiver dated as of
October 10, 2001 (collectively, the "ORIGINAL
LICENSE AGREEMENT"), pursuant to
which, among other things, Alliance granted certain rights and licenses to the
Alliance Patents and Alliance undertook certain action to develop and market
Products and Schering undertook certain action to develop and market Products;
WHEREAS, the Parties intend to enter into a restructured relationship under
the terms and conditions hereinafter set forth;
WHEREAS, the Parties intend to record, characterize and report their
activities under this Agreement as separate activities of each of the Parties;
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
covenants and agreements contained herein, the Parties hereto, intending to be
legally bound, do hereby agree as follows:
ARTICLE I
DEFINITIONS
SECTION 1.01. DEFINITIONS. The following terms, when capitalized, shall
have the following meanings (such meanings to be equally applicable to both the
singular and plural forms of the terms defined) as used in this Agreement:
"AFFILIATE" means any person, corporation, partnership, firm, joint venture
or other entity which, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with,
Alliance or Schering, as the case may be. As used in this definition, "control"
means the possession of the power to direct or cause the direction of the
management and policies of an entity, whether through the ownership of the
outstanding voting securities or by contract or otherwise.
"AF0150" means a white powder *
which, after reconstitution with
appropriate diluent, forms an aqueous suspension of
perfluorohexane/nitrogen-filled microbubbles with the formulation employed in
Phase II Clinical Trials under the United States IND 49,978.
"ALLIANCE HI PATENT" means the Patents listed on Exhibit C.
"ALLIANCE KNOW-HOW" means Information which is within the Control of
Alliance and relates to the research, development, manufacture, use,
importation, sale or offer for sale of the Product. Notwithstanding anything
herein to the contrary, Alliance Know-How shall exclude Alliance Patents.
"ALLIANCE PATENT" means a Patent which covers the research, development,
manufacture, use, importation, sale or offer for sale of a Product, which Patent
is owned or Controlled by Alliance, including, but not limited to:
(a) any patent listed in Exhibit B hereto or added thereto by written
agreement of the Parties during the term of this Agreement;
(b) any patent application listed in exhibit B hereto or added thereto by
written agreement of the Parties during the term of this Agreement; and any
division, continuation, or continuation-in-part of any such application; and any
patent which shall issue based on such application, division, continuation or
continuation-in-part;
(c) any patent which is a reissue, reexamination or extension of any
patent described in (a) or (b) above;
(d) any foreign counterpart patent application or patent corresponding to
any patent identified in (a), (b), or (c), above which is filed or issued in any
country in the Alliance Territory; and
(e) any patent or patent application related to or based on any Alliance
Know-How related to the Product or the manufacture thereof developed or acquired
by alliance prior to or during the term of this Agreement and which is necessary
for the use, development, manufacture, market, sale or distribution of any
marketed Product and any division, continuation or continuation-in-part of any
such patent or patent application; and any patent which shall issue based on
such application, division, continuation or continuation-in-part; and any patent
which is a reissue, reexamination or extension of any such patent.
----------
* Indicates information that has been omitted because confidential treatment has
been requested and filed separately with the Securities and Exchange
Commission.
2
"ALLIANCE TERRITORY" *
"ALLIANCE PAYMENTS" means all payments made by Alliance to Schering
pursuant to Section 5.02 and all payments made by Alliance to Schering which are
not required to be made pursuant to this Agreement or otherwise.
"AUDIT DISAGREEMENT" shall have the meaning set forth in Section 10.03(b).
"BANKRUPTCY EVENT" shall have the meaning set forth in Section 11.02(c).
"BERLEX" means Berlex Laboratories, Inc., a Delaware corporation.
"BUSINESS DAY" means a day that is not a Saturday or Sunday in the United
States or a day on which banking institutions chartered by the State of
New York
or the United States are required or authorized to be closed.
"CAD INDICATION"*
"CLINICAL WORK" means any work related to human trials to assess the
dosing, safety and/or efficacy of a Product and/or to assess a dose and
treatment plan employing such Product, including, but not limited to, Phase III
Clinical Trials and Phase IV Clinical Trials (in the event such Phase IV
Clinical Trials are required by the FDA).
"COMMERCIALIZATION" and "COMMERCIALIZE" shall refer to all activities
undertaken relating to the pre-marketing, marketing and sale of a Product.
"COMPETITIVE PRODUCT" means a perfluorocarbon-based product which has
obtained Regulatory Approval for use as an ultrasound contrast agent and such
use is included in the labeling of such product.
"CONFIDENTIAL INFORMATION" shall have the meaning set forth in
Section 7.01.
"CONTROL" or "CONTROLLED" shall refer to possession of the ability to grant
a license or sublicense of patent rights, know-how or other intangible rights as
provided for herein without violating the terms of any agreement or other
arrangement with any Third Party.
"COST OF GOODS " means the cost of Product inventory and other
manufacturing costs incurred with respect to the Product sold. Cost of Goods
shall be calculated in the manner set forth in Exhibit A.
3
"DEVELOPMENT" and "DEVELOP" shall refer to all activities relating to
obtaining Regulatory Approval of a Product, and all activities relating to
developing the ability to manufacture the same. This includes preclinical
testing, toxicology, formulation, bulk production, fill/finish, manufacturing
process development, manufacturing, quality assurance and quality control
technical support, clinical studies, regulatory affairs and outside counsel
regulatory legal services.
"DEVELOPMENT EXPENSES" means the expenses incurred in connection with the
Development of a Product. Development Expenses shall include, but are not
limited to, toxicological, pharmacokinetic, metabolic or clinical aspects of a
Product conducted internally or by individual investigators, of design and
manufacture of any required prototype devices, of consultants necessary for the
purpose of obtaining and/or maintaining Regulatory Approval of a Product in the
Alliance Territory, and costs (and related fees) for preparing, submitting,
reviewing or developing data or information for the purpose of submission to a
governmental authority to obtain and/or maintain Regulatory Approval of a
Product in the Alliance Territory.
"DMF" shall have the meaning set forth in Section 6.06.
"DOLLARS" means the lawful currency of the United States of America.
"DOWNPAYMENT" means any lump sum payment to Alliance for any rights to
market or manufacture the Product in the Alliance Territory, specifically
excluding payments (i) for the purchase of equity as Alliance at fair market
value or (ii) based on sales of the Product.
"DRUG APPROVAL APPLICATION" means an application for Regulatory Approval
required to be approved before commercial sale or use of a Product as a drug in
a regulatory jurisdiction, including, for the purposes of Regulatory Approval in
the United States, a New Drug Application and all supplements filed pursuant to
the requirements of the FDA (including all documents, data and other information
concerning a Product which are necessary for, or included in, FDA approval to
market the Product, as more fully defined in 21 C.F.R. Sections 314.1 et seq.).
"EFFECTIVE DATE" shall have the meaning set forth in the heading to this
Agreement.
"EUR" means the lawful currency of the European Monetary Union.
"EUROPE" means the countries which are members of the European Union as
such membership may change from time to time.
"FDA" means the United States Food and Drug Administration, or any
successor agency.
"FIELD" means, at any date of determination, the development, use,
manufacture, distribution, marketing and sale of the Product as an ultrasound
contrast agent in all possible indications, in humans or animals.
4
"FIRST COMMERCIAL SALE" means the date a Party or its Affiliate or a
sublicensee of a Party first sells commercially, pursuant to a Regulatory
Approval, a Product in any country of the Alliance Territory or the Schering
Territory, as the case may be, provided, however, that where such a first
commercial sale has occurred in a country for which pricing or reimbursement
approval is necessary for widespread sale, then such sales shall not be deemed a
First Commercial Sale until such pricing or reimbursement approval has been
obtained.
"FIRST PERIOD" means the period commencing on the First Commercial Sale and
ending on the third anniversary of the First Commercial Sale.
"FULLY LOADED COSTS" means all internal and external costs incurred by
Berlex in the performance of the services described in Section 6.09(a) as
determined by United States Generally Accepted Accounting Principles, applied on
a consistent basis, which shall include without limitation the following costs:
carrying costs of inventories, direct and indirect labor costs, material costs,
and direct and indirect overhead. Fully Loaded Costs of Berlex also shall
include all set up costs necessary for Berlex to perform the functions described
in Section 6.09(a), regardless of depreciation schedules which may have been
established to absorb such costs over a period of time longer than the period
during which Berlex will be performing the described services for Alliance.
"INFORMATION" means (i) techniques and data within the Field relating to
the Product, including, but not limited to, inventions, practices, methods,
knowledge, know-how, skill, trade secrets, experience, test data including
pharmacological, toxicological, preclinical and clinical test data, regulatory
submissions, adverse reactions, analytical and quality control data, marketing,
pricing, distribution, cost, sales and manufacturing data or descriptions and
(ii) compounds, compositions of matter, assays and biological materials within
the Field relating to the Product.
"LOSSES" shall have the meaning set forth in Section 12.01(a).
"LV INDICATION"*
"MANUFACTURING PARTY" means the Party who is responsible for the (i)
manufacturing and supply of the Product for use during Development or (ii)
commercial manufacture and supply of the Product.
"MAXIMUM PAYMENT" shall have the meaning set forth in Section 5.01(a)(ii).
"MINIMUM DOWNPAYMENT SHARE"*
5
"NET SALES" means the amount invoiced by a Party, its Affiliates or its
sublicensees from sales of the Product to Third Parties, less reasonable and
customary deductions applicable to the Product for (i) transportation charges
and charges such as insurance, relating thereto paid by the selling party; (ii)
sales and excise taxes or customs duties paid by the selling party and any other
governmental charges imposed upon the sale of the Product and paid by the
selling party; (iii) distributors' fees, rebates or allowances actually granted,
allowed or incurred; (iv) quantity discounts, cash discounts or chargebacks
actually granted, allowed or incurred in the ordinary course of business in
connection with the sale of the Product; (v) allowances or credits to customers,
not in excess of the selling price of the Product, on account of governmental
requirements, rejection, outdating, recalls or return of the Product; (vi) costs
of customer programs such as cost effectiveness or patient assistance programs
designed to aid in patient compliance to maintain medication schedules; and
(vii) a one percent (1%) deduction for bad debts. For the purpose of calculating
a Party's Net Sales, the Parties recognize that (a) a Party's customers may
include persons in the chain of commerce who enter into agreements with a Party
as to price even though title to the Product does not pass directly from a Party
to such customers, and even though payment for such Product is not made by such
customers directly to a Party and (b) in such cases chargebacks paid by a Party
to or through a Third Party (such as a wholesaler) can be deducted by a Party
from gross revenue in order to calculate a Party's Net Sales. Any deductions
listed above which involve a payment by a Party shall be taken as a deduction
against aggregate sales for the period in which the payment is made. Sales of
the Product between a Party and its Affiliates or sublicensees solely for
research or clinical testing purposes shall be excluded from the computation of
Net Sales. Net Sales will be accounted for in accordance with international
accounting standards consistently applied.
"NON-MANUFACTURING PARTY" shall be any Party that is not a Manufacturing
Party.
"OPTION 1" means the option provided in Section 4.01(b).
"OPTION 1 EFFECTIVE DATE" means the date which is ninety (90) days
following the date on which Alliance gives Schering written notice of its intent
to exercise Option 1 in accordance with Section 4.01(b) and Section 13.06.
"OPTION 2" means the option provided in Section 4.01(c).
"OPTION 2 EFFECTIVE DATE" means the date which is ninety (90) days
following the date on which Alliance gives Schering written notice of its intent
to exercise Option 2 in accordance with Section 4.01(c) and Section 13.06.
"PATENT" means (i) valid United States and foreign patents,
re-examinations, reissues, renewals, extensions, term restorations, divisionals,
continuations and continuations-in-part thereof, and foreign counterparts
thereof, and (ii) pending applications for United States and foreign patents and
foreign counterparts thereof. "PATENT" also includes a Supplementary Certificate
of Protection of a member state of the European Community and any other similar
protective rights in any other country.
6
"PATENT EXPENSES" means the fees, expenses and disbursements and outside
counsel fees, and payments to Third Party agents incurred in connection with the
preparation, filing, prosecution and maintenance of Alliance Patents covering
the Product within the Field, including Alliance's costs of patent interference
and opposition proceedings and actions at law and equity for patent infringement
and any sums paid to Third Parties on account of judgments or settlements
arising out of Third Party patent claims (other than such judgments or
settlements resulting in the payment of royalties).
"PHASE II CLINICAL TRIALS" has the meaning ascribed thereto in 21 C.F.R.
Section 312.21(b), as amended from time to time.
"PHASE III CLINICAL TRIALS" has the meaning ascribed thereto in 21 C.F.R.
Section 312.21(c), as amended from time to time.
"PHASE IV CLINICAL TRIALS" means product support clinical trials of a
Product commenced after receipt of Regulatory Approval in the United States for
such Product. These trials shall be considered a part of Clinical Work.
"PRODUCT" means AF0150 and any drug compounds, drug compositions and
medical devices and systems related to perfluorocarbon containing ultrasound
imaging products and developed by Alliance pursuant to this Agreement (and with
Schering pursuant to the Original
License Agreement) which, in the absence of
this Agreement, the use, development, manufacture, marketing, sale or
distribution of which would result in the infringement of one or more claims in
an Alliance Patent or which utilize the Alliance Know-How. For ease of
reference, "Product" is generally expressed in the singular in this Agreement,
but multiple Products may be Developed or marketed hereunder.
"REGULATORY APPROVAL" means any approvals, product and/or establishment
licenses, registrations or authorizations of any federal, state or local
regulatory agency, department, bureau or other governmental entity, necessary
for the manufacture, use, storage, importation, export, transport or sale of
Product in a regulatory jurisdiction.
"RESTATEMENT DATE" shall have the meaning set forth in the heading to this
Agreement.
"ROYALTY AVERAGE" shall have the meaning set forth in Section 5.01(a)(iv).
"ROYALTY PERCENTAGE" shall have the meaning set forth in Section 5.01.
"SCHERING TERRITORY"*
7
"SCHERING HI PATENT" means the patents listed on Exhibit D.
"SCHERING RECOUPMENT GOAL"*
"SECOND PERIOD" means the period commencing on the third anniversary of the
First Commercial Sale and ending on the fourth anniversary of the First
Commercial Sale.
"SIGNIFICANT CHANGE" means any change requiring prior approval by the FDA
or contemporaneous submission to the FDA of a supplement pursuant to 21 C.F.R.
Sections 314.70(b) or (c), as amended from time to time, if such change is made
subsequent to FDA approval of the Drug Approval Application in the United
States.
"THIRD PARTY" means any entity other than Alliance or Schering and their
respective Affiliates and sublicensees.
"THIRD PERIOD" means the period commencing on the fourth anniversary of the
First Commercial Sale and ending on the fifth anniversary of the First
Commercial Sale.
"TV INDICATION"*
"WRITTEN DISCLOSURE" shall have the meaning set forth in Section 7.06.
ARTICLE II
DEVELOPMENT
SECTION 2.01. DEVELOPMENT. Alliance shall use such efforts as it deems
reasonable to execute and substantially perform all Development work for the
Product; provided, however,*
8
SECTION 2.02. DRUG APPROVAL APPLICATIONS.
(a) RESPONSIBILITY. Alliance shall be responsible in the Alliance
Territory for preparing and filing Drug Approval Applications and seeking
Regulatory Approvals for the Product, including preparing all reports necessary
as part of a Drug Approval Application. All such Drug Approval Applications
shall be filed in the name of Alliance. Alliance shall be responsible for
prosecuting such Drug Approval Applications. In the event that any regulatory
agency threatens or initiates any action to remove a Product from the market,
Alliance shall notify Schering of such communication within one Business Day of
receipt by Alliance so long as Schering has, or may have, marketing rights under
Article IV.
(b) OWNERSHIP. Alliance shall be the legal and beneficial owner of all
Drug Approval Applications and related approvals in the Alliance Territory. If
Schering chooses to market a Product (as co-marketing partner or on its own),
Schering shall have the right, but not the obligation to own the Drug Approval
Application.
SECTION 2.03. COSTS OF DEVELOPMENT. All Development Expenses incurred by
Alliance for a Product shall be borne by Alliance.
SECTION 2.04. RIGHT TO ENGAGE THIRD PARTIES. In the course of its business,
Alliance regularly uses Third Parties to perform certain Development activities.
Alliance may continue to do so during the course of this Agreement; provided,
however, that any expenses relating to such Third Party Development will be
incurred and borne by Alliance at its sole expense.
SECTION 2.05. SCHERING PORTFOLIO. Alliance is aware of the fact that
Schering was, as of the Effective Date, and is, as of the Restatement Date,
manufacturing and selling Competitive Products in certain countries of the
Alliance Territory and will continue to do so in any country of the Alliance
Territory suitable, in Schering's view, for such marketing. Alliance agrees that
nothing in this Agreement is intended to prevent or prevents Schering from such
marketing at its sole discretion.
ARTICLE III
LICENSES
SECTION 3.01. PATENT LICENSE TO SCHERING.
(a) ALLIANCE PATENTS. Alliance grants to Schering an exclusive license
(even as to Alliance) under the Alliance Patents and the Alliance Know-How to
develop, market, sell, and distribute the Product in the Schering Territory.*
(b) ALLIANCE HI PATENTS. Alliance grants to Schering a non-exclusive
worldwide license, without a right to sublicense to any other party than
Affiliates, under the
9
Alliance HI Patents to use, develop, manufacture, have manufactured, market,
sell and distribute product for use as an ultrasound contrast agent.
SECTION 3.02. PATENT AND TRADEMARK LICENSE TO ALLIANCE.
(a) SCHERING HI PATENTS. Schering grants to Alliance a non-exclusive
worldwide, royalty-free license, without a right to sublicense, under the
Schering HI Patents to use, develop, manufacture, have manufactured, market,
sell and distribute the Product worldwide for all indications in the Field;
provided, however, that Schering agrees to negotiate in good faith the terms on
which Alliance would be permitted to sublicense Schering HI Patents to contrast
agent manufacturers promptly upon presentation by Alliance of a proposal for
such a sublicense (for the avoidance of doubt, Schering has no obligation to
enter into any such negotiations which regard to a proposed sublicense for the
manufacture of ultrasound equipment).
(b) SCHERING TRADEMARK. At Alliance's election, Schering shall grant to
Alliance a non-exclusive royalty-free license in the Alliance Territory, without
a right to sublicense, for the use of the trademark "Imavist" to be used in
connection with the purposes of this Agreement, such license to terminate as of
the first anniversary of the First Commercial Sale.
SECTION 3.03. THIRD PARTY TECHNOLOGY.
(a) EXISTING LICENSES. The licenses granted under Section 3.01 include
sublicenses of Third Party technology existing on the Effective Date and
licensed to Alliance to the extent that such sublicenses can be so granted. Any
royalties payable to Third Parties pertaining to technology discussed in the
previous sentence shall either be paid by Alliance or be offset or deducted from
royalty payments as provided under Section 5.01.
(b) SUBJECT TO TERMS. The licenses granted under this Section 3.01, to the
extent they include sublicenses of Third Party Technology, Shall be subject to
the terms and conditions of the
license agreement pursuant to which the
sublicense is granted. as of the Effective Date and as of the Restatement Date
hereof there are no such agreements in place.
(c) FUTURE THIRD PARTY ROYALTIES.*
10
ARTICLE IV
COMMERCIALIZATION
SECTION 4.01. MARKETING.
(a) ALLIANCE TERRITORY AND SCHERING TERRITORY. Subject to Section 4.01(d),
Alliance shall be the sole marketing Party with respect to the Product in the
Alliance Territory. Subject to Sections 4.01(b) and 4.01(c), Schering shall be
the sole marketing Party with respect to the Product in the Schering Territory;
provided, however, that Schering has no obligation to Develop or Commercialize
the Product in the Schering Territory.
(b) OPTION 1.*
(c) OPTION 2.*
(d) CO-MARKETING, CO-PROMOTION.*
SECTION 4.02. TAX CONSIDERATIONS. Either Party may take advantage of tax
considerations which benefit it and not the other Party. In the event that a
Party takes advantage of a tax consideration in connection with a Product which
benefits it and not the other Party, no compensation to the other Party shall be
required; provided, however, that no negative tax implication for the other
Party may be an element of such tax benefit.
11
ARTICLE V
ROYALTIES
SECTION 5.01. SCHERING PRODUCT ROYALTIES. In further consideration of the
rights and licenses granted to Schering under Section 3.01(a) and Section
3.01(b) of this Agreement, Schering shall pay to Alliance the following
royalties based on the Net Sales of the Product in the Schering Territory (the
"ROYALTY PERCENTAGE"):
(a) SALES IN THE SCHERING TERRITORY. With respect to sales of the Product
in the Schering Territory, Schering shall pay royalties in accordance with the
following table:
(i) Subject to Section 5.01(b), Schering shall pay to Alliance a
royalty on Net Sales of the Product in accordance with the following table:
Maximum Payment Royalty Average
Total Net Sales/Year Royalty Percentage (% of Net Sales) (% of Net Sales)
Category ($ millions) (% of Net Sales) (Section 5.01(a)(ii)) (Section 5.01(a)(iv))
-------- ------------ ---------------- --------------------- ---------------------
1. * * *
2. * * * *
3. * * * *
4. * * * *
5. * * * *
(ii) In any calendar year*
shall not exceed*
any such amount exceeding the Maximum Payment shall be
reimbursed by Alliance to Schering. Any * made in
accordance with this Section 5.01(a) shall be made after the end of the
calendar year for which such adjustment is applicable, and any amount*
Alliance
ratably over the next four (4) quarters. Reasonably detailed accounting
records to support such adjustments shall be provided to Alliance within sixty
(60) days after the end of the calendar year.
(iii) Notwithstanding Section 5.01(a)(i) above, in the event Net Sales
of Product*
Net Sales For*
12
Net Sales * of such total. Schering shall
make such adjustments at the end of the first calendar quarter of the year and
shall deliver any necessary payments (with reasonably detailed records of such
adjustments) to Alliance within sixty (60) days after the end of the first
calendar quarter of such year.
(iv) Notwithstanding Section 5.01(a)(i) above,*
applicable for total Net Sales for the immediately
preceding calendar year. Adjustments from amounts paid as royalties pursuant
to this section to amounts actually earned as royalties shall be made to
fourth quarter payments to Alliance (with reasonably detailed records of such
adjustments provided therewith).
(b) MINIMUM PAYMENTS. Notwithstanding anything to the contrary in
Section 5.01*
on a country-by-country basis,*
If this Section 5.01(b) becomes applicable, *
The
minimum payments referred to in this Section 5.01(b)*
(c) THIRD PARTY ROYALTIES. In the event that after the First Commercial
Sale in the Schering Territory, Alliance pays any royalties to Third Parties*
(d) ROYALTY REDUCTION. If the Product is sold in any country in which
Alliance does not have valid patent coverage for the Product which would prevent
the sale of a generic form of the Product, the royalty obligation set forth in
Section 5.01 above with respect to Net Sales attributable to the sale of the
product in such country shall be reduced *
Net Sales attributable to the
13
sale of the Product in such country unless and until Alliance is granted such
valid patent coverage for the Product in such country; provided that *
(e) ROYALTY TERM. Except where expressly provided otherwise in this
Agreement, all royalties to a Alliance shall be paid, on a country-by-country
basis, from the date of the First Commercial Sale of a Product in a country in
the Schering Territory until the later of (i) ten (10) years from the First
Commercial Sale in such country or (ii) the last to expire of any valid Alliance
Patents which covers the use or sale of the Product in such country.
(f) DISCONTINUANCE. Subject to the provisions of Article XI, Schering may
discontinue Commercialization of a Product at any time.
(g) LICENSE FOLLOWING EXPIRATION. Upon expiration of the royalty term for
a Product in the country as described above, Schering shall thereafter have an
exclusive (even as to Alliance), paid-up license to Alliance Know-How to sell,
offer for sale, have sold and import that Product in that country. In such
event, Schering shall retain responsibility for, and indemnify Alliance from,
the payment of all applicable royalties and other obligations owed to a Third
Party with respect to the Product.
(h) APPLICABILITY. This Section 5.01 shall be applicable to (i) sales of
the Product for the TV Indication until such time as Alliance becomes the sole
marketing Party with respect to the Product for the TV indication in all the
countries of the world pursuant to Section 4.01(b) and (ii) sales of the Product
in all the countries of the world except the United States of America for the
CAD Indication until such time as Alliance becomes the Sole marketing Party with
respect to the Product in all of the countries of the world for all indications,
excluding however the TV Indication, pursuant to Section 4.01(c).
SECTION 5.02. ALLIANCE ROYALTIES. In consideration of funds invested by
Schering in the Development of the Product under the Original
License Agreement,
Alliance shall make the following payments to Schering.
(a) DOWNPAYMENT. Alliance shall pay to Schering a payment equal to *
of any Downpayment received by Alliance during the period *
PROVIDED HOWEVER, that any
payment pursuant to this Section 5.02(a) shall at least equal the Minimum
Downpayment Share.
(B) ROYALTY WITH MINIMUM DOWNPAYMENT SHARE. In the event that Schering
receives the Minimum Downpayment Share pursuant to Section 5.02(a), Alliance
shall pay to Schering a royalty payment equal to, on a country-by-country basis,
the following: *
(i) * of Net Sales of Product in the Alliance
Territory in the event that Alliance does not exercise either Option 1 or
Option 2;
(ii) * of Net Sales of Product in the
event that Alliance exercises Option 2 but not Option 1;
14
(iii) * of Net Sales of Product in the
event that Alliance exercises Option 1 but not Option 2; and
(iv) * of Net Sales of Product in the event
that Alliance exercises both Option 1 and Option 2.
(c) ROYALTY WITHOUT MINIMUM DOWNPAYMENT SHARE. In the event that Schering
does not receive the Minimum Downpayment Share pursuant to Section 5.02(a),
Alliance shall pay to Schering a royalty payment equal to, on a
country-by-country basis, the following:
(i) * of Net Sales of Product in the
Alliance Territory in the event that Alliance does not exercise either
Option 1 or Option 2;
(ii) * of Net Sales of Product in the
event that Alliance exercises Option 2 but not Option 1;
(iii) * of Net Sales of Product in the
event that Alliance exercises Option 1 but not Option 2; and
(iv) * of Net Sales of Product in the event
that Alliance exercises both Option 1 and Option 2.
(d) ROYALTY REDUCTION. Any royalty payments payable pursuant to Section
5.02 shall be reduced, on a country-by-country basis, as set forth below:
(i) *
(ii) *
(iii) *
(iv) *
(e) ROYALTY TERM. Except where expressly provided otherwise in this
Agreement, all royalties to Schering shall be paid, on a country-by-country
basis, from the First
15
Commercial Sale of a Product in a country in the Alliance Territory until the
fifth anniversary of such First Commercial Sale in such country.
(f) DISCONTINUANCE. Subject to the provisions of Article XI, Alliance may
discontinue Commercialization of a Product at any time.
SECTION 5.03. ROYALTY REPORTS AND PAYMENTS. Each Party shall make royalty
payments to the other Party within sixty (60) days after the end of each
calendar quarter in which Net Sales by the Party making such royalty payment
occurred. A report summarizing the Net Sales of the Products by each Party
during the relevant quarter on a country-by-country basis shall be delivered to
the other Party within sixty (60) days following the end of each calendar
quarter for which royalties are due.
SECTION 5.04. PAYMENTS; INTEREST.
(a) BUSINESS DAY. Any payments due under this Agreement shall be due on
such date as specified in this Agreement and, in the event such date is a day on
which commercial banks are not authorized to conduct business in either San
Diego, California or Berlin, Germany, then the next succeeding business day, and
shall be made by wire transfer to a designated bank account of the receiving
Party.
(b) INTEREST. Any failure by a Party to make a payment within five days
after the date when due shall obligate such Party to pay interest during the
period commencing on the due date and ending on the payment date to the
receiving Party at a rate per annum equal to*
and, in the event such a rate is not quoted on such date then on the
immediately preceding date such rate is quoted. The interest rate shall be
adjusted whenever there is a change*
Interest shall be compounded annually in arrears. Such interest shall
be due and payable upon the payment of the underlying principal otherwise due
and payable.
SECTION 5.05. TAXES. The Party receiving royalties shall pay any and all
taxes levied on account of royalties it receives under this Agreement. If laws
or regulations require that taxes be withheld, the selling Party will (i) deduct
those taxes from the remittable royalty, (ii) timely pay the taxes to the proper
taxing authority, and (iii) send proof of payment to the other Party within
thirty (30) days of receipt of confirmation of payment from the relevant taxing
authority. The selling Party agrees to take all lawful and reasonable efforts to
minimize such taxes to the other Party.
SECTION 5.06. PAYMENTS TO OR REPORTS BY AFFILIATES. Any payment required
under any provision of this Agreement to be made to either Party or any report
required to be made by any Party shall be made to or by an Affiliate of that
Party if designated by that Party as the appropriate recipient or reporting
entity without relieving such party from responsibility for such payment or
report.
16
SECTION 5.07. PAYMENT CURRENCY. Payments by under this Agreement shall be
paid in Dollars by wire transfer of immediately available funds to an account at
a commercial bank designated by Alliance or Schering pursuant to this Article V
at least ten (10) business days before payment is due. Where payments are based
on Net Sales in countries other than the United States, the amount of such Net
Sales expressed in the currency of each country shall be converted into Dollars
by Schering or Alliance, respectively, as set forth below:
(i) SCHERING: The calculation of royalty payments within Schering is
based upon EUR. Therefore, where payments are based on Net Sales in countries
other than the member states of the European Monetary Union, the amount of
such Net Sales expressed in the currency of each country shall be converted
into EUR at the Euro Foreign Exchange Reference Rates published by the
European Central Bank in Frankfurt / Main, Germany on the last Business Day of
the applicable calendar quarter. The resulting EUR amount will be converted
into Dollars again at the Euro Foreign Exchange Reference Rates published by
the European Central Bank in Frankfurt / Main, Germany on the last Business
Day of the applicable calendar quarter. These Euro Foreign Exchange Reference
Rates are, as of the effective date, published on REUTERS screen < ECB37 >. If
no Euro Foreign Exchange Reference Rate is determined for the relevant
currency the parties shall agree upon another reference rate.
(ii) ALLIANCE: The calculation of royalty payments within Alliance is
based upon Dollars. Therefore, where payments are based on Net Sales in
countries other than the United States, the amount of such Net Sales expressed
in the currency of each country shall be converted into Dollars at the 12 p.m.
Buying Rates published by the Federal Reserve Bank of
New York on REUTERS
screen < FEDSPOT > on the last business Day of the applicable calendar
quarter. if no 12 p.m. Buying Rate is determined for the relevant currency the
parties shall agree upon another reference rate.
ARTICLE VI
MANUFACTURE AND SUPPLY
SECTION 6.01. MANUFACTURE AND SUPPLY BY ALLIANCE. Alliance shall use
commercially reasonable efforts, subject to the greater of the capacity of
Alliance's San Diego manufacturing facility as of the date hereof or the date of
filing of the Drug Approval Application for the United States, to manufacture,
or arrange for manufacture of Schering's, or its Affiliates' requirements of at
least * of the Product per calendar year ("the Minimum Capacity") for
supply to Schering for the Commercialization of the Product in each applicable
country in the Schering Territory and/or the Commercialization of the Product in
the Alliance Territory after Schering has exercised its option according to
Section 4.01(d). Schering hereby agrees to purchase all of its requirements of
the Product from Alliance.
SECTION 6.02. MANUFACTURING AND SUPPLY AGREEMENT. As soon as it is clear
that Schering will Commercialize the Product, the Parties will negotiate and
execute in good faith a manufacturing and supply agreement which shall at least
contain, but shall not be limited
17
to, terms on the following topics: orders and forecasts, quality testing and
quality control, GMP and regulatory compliance, change management, record
keeping, audits and inspection rights, delivery/acceptance/rejections of
products, shipment, failure of delivery, product complaints and recalls,
technology transfer in case of failure to supply, pharmaceutical
responsibilities, joint manufacturing committee, term and termination, and a
detailed quality assurance agreement as appendix.
SECTION 6.03. STEP-IN RIGHT OF SCHERING. Notwithstanding Section 6.01
Schering shall have the right, but not the obligation, to become the
manufacturer for its own requirements of the Product
(a) if Alliance is not capable of manufacturing, or arranging for
manufacture all of Schering's, or its Affiliates' requirements up to the Minimum
Capacity, Alliance shall notify Schering sufficiently in advance, but at least
six (6) months prior to the then required transfer of the manufacturing process;
(b) upon two (2) years advanced written notice to Alliance in accordance
with Section 13.06 that Schering intends to become a manufacturing party for
Schering's, or its Affiliates' requirements of the Product.
SECTION 6.04. TECHNOLOGY AND KNOW-HOW TRANSFER.
(a) In the event Schering becomes a manufacturer of the Product pursuant
to Section 6.03 or Section 6.08, Alliance will transfer to Schering all relevant
and necessary technology and know-how related to the manufacturing process,
including but not limited to manufacturing descriptions, master batch records,
executed batch records, release specifications and release testing methods (for
active pharmaceutical ingredients, other raw materials, packaging material and
finished products), in process testing methods, in process specifications,
annual product reviews, validation reports, techniques and formulae, equipment
descriptions in order to enable Schering to manufacture the Product for its, or
its Affiliates' requirements of Product.
(b) Such transfer shall be done in close coordination with Schering as
promptly as possible after receipt of Schering's notice that Schering wants to
become a manufacturing party for the Product.
(c) Alliance will allow and enable Schering to contact the relevant
personnel at Alliance to facilitate the transfer.
(d) Alliance will, at Schering's cost, give the necessary support and
advice to Schering during the transfer and with regard to registration and
regulatory issues linked to such transfer of Product production to a new
production site.
SECTION 6.05. REGULATORY APPROVAL FOR MANUFACTURING. Alliance shall use
commercially reasonable efforts to make necessary filings to obtain, or to cause
a Third Party manufacturer to make necessary filings to obtain, Regulatory
Approval for the manufacture of
18
the Product as part of the approval of a Drug Approval Application for each
Product. Alliance shall notify Schering without delay of all changes to the
process for the manufacture of the Product or its drug substance, whether such
changes are Significant Changes or not.
SECTION 6.06. DMF. Alliance shall be responsible for all testing and
document generation (including without limitation all facilities information and
related documentation; chemistry, manufacturing, and control information;
regulatory methods and controls; assays and reference standards) necessary for
filing a drug master file ("DMF") with the FDA for the production of the drug
substance from which each Product is formulated. Alliance shall also be
responsible for filing such DMF with the FDA for the production of the drug
substance from which each Product is formulated.
SECTION 6.07. ACCEPTANCE AND PRICING. With respect to Product that Alliance
supplies to Schering for sale,*
Schering shall have the right to test Products
upon delivery at its expense for compliance with specifications and legal and
regulatory requirements*
(i) *
(ii) *
SECTION 6.08. COMPETITIVE COST OF GOODS. If Schering is able to manufacture
or to have manufactured the Product for its or its Affiliates' requirements at*
SECTION 6.09. PACKAGING
(a) BERLEX. Schering shall cause Berlex to perform or have performed those
services relating to the packaging of the Product for the United States market
until such time as Alliance or a designee of Alliance obtains Regulatory
Approval to perform such services, but not to exceed one (1) year. Alliance
shall use diligent efforts to obtain such Regulatory Approval as promptly as
possible. As compensation for such services by Berlex, or under Berlex's
direction,*
In the event that Berlex performs the services described above for Alliance for
more than one (1) year, then for such additional period,*
19
(b) SCHERING PACKAGING. Products manufactured by Alliance shall be
supplied to Schering in packaged form as Schering reasonably directs after
consultation with Alliance. Packaging and labeling costs incurred by Alliance
and/or Schering shall be included in Costs of Goods Sold.
ARTICLE VII
CONFIDENTIALITY
SECTION 7.01. CONFIDENTIALITY; EXCEPTIONS. Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree
that the receiving Party shall keep confidential and shall not publish or
otherwise disclose or use for any purpose other than as provided for in this
Agreement any Information and other information and materials furnished to it by
the other Party pursuant to this Agreement or any Information developed during
the course of the collaboration hereunder, or any provisions of this Agreement
that are the subject of an effective order of the United States Securities
Exchange Commission granting confidential treatment pursuant to the United
States Securities Act of 1934, as amended (collectively, "CONFIDENTIAL
INFORMATION"), except to the extent that it can be established by the receiving
Party that such Confidential Information:
(a) was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the other Party;
(b) was generally available to the public or otherwise part of the public
domain at the time of its disclosure to the receiving Party;
(c) became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of
the receiving Party in breach of this Agreement;
(d) was disclosed to the receiving Party, other than under an obligation
of confidentiality, by a Third Party who had no obligation to the disclosing
Party not to disclose such information to others; or
(e) was independently discovered and/or developed by the receiving Party
as documented in its corporate records.
SECTION 7.02. AUTHORIZED DISCLOSURE. Each Party may disclose Confidential
Information hereunder to the extent such disclosure is reasonably necessary in
filing or prosecuting patent applications, prosecuting or defending litigation,
filing or updating any Drug Approval Application, complying with applicable
governmental regulations or conducting pre-clinical or clinical trials,
provided that if a Party is required by law or regulation to make any such
disclosures of the other Party's Confidential Information it will, except where
impracticable for necessary disclosures, for example in the event of medical
emergency, give reasonable advance notice to the other Party of such disclosure
requirement and, except to the extent inappropriate in the case of patent
applications, will use its reasonable efforts to secure confidential treatment
of such Confidential Information required to be disclosed. In addition,
20
and with prior notice to the other Party of each Third Party with whom a
confidential disclosure agreement is being entered into, each Party shall be
entitled to disclose, under a binder of confidentiality, Confidential
Information to any Third Party for the purpose of carrying out the purposes of
this Agreement. Nothing in this Article VII shall restrict any Party from using
for any purpose any Confidential Information independently developed by it
during the course of the collaboration hereunder, or from using Confidential
Information that is specifically derived from pre-clinical or clinical trials to
carry out Regulatory Approval, marketing, sales or professional services support
functions as is customary in the pharmaceutical industry.
SECTION 7.03. SURVIVAL. This Article VII shall survive the termination or
expiration of this Agreement.
SECTION 7.04. TERMINATION OF PRIOR AGREEMENT. This Agreement supersedes
the Secrecy Agreement between Alliance and Schering dated as of January 14,
1997. All Information exchanged between the Parties under that Agreement shall
be deemed Confidential Information and shall be subject to the terms of this
Article VII.
SECTION 7.05. PUBLICATIONS. Prior to the launch of a Product, Alliance will
determine the overall strategy for publication in support of such Product.
Notwithstanding any term of Section 7.06 below, the Parties recognize the need
for scientific publications pertaining to development of the Product and the
Parties will cooperate to provide for such publications; provided, however, that
the right of any Party to withhold or delay consent to publish or delay
publication shall be subject to any contractual publication rights of Third
Parties involved in research or clinical trials for the Product. The Parties
will use reasonable efforts to obtain the voluntary consent of any Third Party
granted publication rights related to the Product prior to the Effective Date to
comply with reasonable notice and timing requests and will promptly review any
publications delivered for review.
SECTION 7.06. PUBLICITY REVIEW. Subject to the further provisions of this
Section 7.06 and Section 10.04, no Party shall originate any written publicity,
news release, or other announcement or statement relating to this Agreement or
to performance hereunder or the existence of an arrangement between the Parties
(collectively, "WRITTEN DISCLOSURE"), without the prior prompt review and
written approval of the other, which approval shall not be unreasonably withheld
or delayed. Notwithstanding the foregoing provisions of this Section 7.06, any
Party may make any public Written Disclosure it believes in good faith based
upon the advice of counsel is required by applicable law or any listing or
trading agreement concerning its publicly traded securities, provided that prior
to making such Written Disclosure, the disclosing Party shall provide the other
Party with a copy of the materials proposed to be disclosed and provide the
receiving Party with an opportunity to promptly review the proposed Written
Disclosure. To the extent that the receiving Party reasonably requests that any
information in the materials proposed to be disclosed be deleted, the disclosing
Party shall request confidential treatment of such information pursuant to Rule
406 of the United States Securities Act of 1933 or Rule 26b-2 of the United
States Securities Exchange Act of 1934, as applicable (or any other applicable
regulation relating to the confidential treatment of information), so that there
be omitted from the materials that are publicly filed any information that the
receiving Party reasonably requests to
21
be deleted. The terms of this Agreement may also be disclosed to (i) government
agencies where required by law, or (ii) Third Parties with the prior written
consent of the other Party, which consent shall not be unreasonably withheld or
delayed, so long as such disclosure is made under a binder of confidentiality
and so long as highly sensitive terms and conditions such as financial terms are
extracted from the Agreement or not disclosed upon the request of the other
Party. All Written Disclosures shall be factual and as brief as is reasonable
under the circumstances. Upon request by either Party, the Parties agree to
prepare a mutually agreed press release and question and answer document with
respect to this Agreement. Each Party agrees that it will use reasonable efforts
to cause all Written Disclosures and oral statements relating hereto to be
consistent with the answers specified in such question and answer document.
ARTICLE VIII
OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS
SECTION 8.01. OWNERSHIP. Each Party shall solely own, and it alone shall
have the right to apply for, Patents within and outside of the United States for
any inventions made solely by that Party's employees or consultants in the
course of performing work under this Agreement.
SECTION 8.02. PATENT FILINGS. Each Party, at its sole discretion and
responsibility, shall prepare, file, prosecute and maintain Patents to cover
discoveries and inventions made solely by its own employees or consultants.
SECTION 8.03. THIRD PARTY PATENT RIGHTS. Each Party agrees to bring to
the attention of the other Party any Third Party Patent it discovers, or has
discovered, and which relates to the subject matter of this Agreement.
SECTION 8.04. ENFORCEMENT RIGHTS.
(a) NOTIFICATION OF INFRINGEMENT. If either Party learns of any
infringement or threatened infringement by a Third Party of the Alliance
Patents, such Party shall promptly notify the other Party and shall provide such
other Party with all available evidence of such infringement.
(b) ENFORCEMENT IN THE TERRITORY. Alliance shall have the right, but not
the obligation, to institute, prosecute and control at its own expense any
action or proceeding with respect to infringement of any Alliance Patents
covering the manufacture, use, importation, sale or offer for sale of the
product being developed or marketed by counsel of its own choice. Where possible
with regard to manpower and time, Schering upon Alliance's request and at
Alliance's costs, shall give documentary support and reasonable assistance in
such proceedings. Any damages or other monetary awards recovered pursuant to
this Section 8.04(b) shall be for the account of Alliance. If Alliance fails or
does not want to bring an action or proceeding or otherwise take appropriate
action to ▇▇▇▇▇ such infringement within a period of one hundred eighty (180)
days of notice by Schering to Alliance requesting such action, Schering shall
have the right, but not the obligation, to institute, prosecute and control at
its own expense any such
22
action or proceeding with respect to infringement of any Alliance patents.*
(c) SETTLEMENT WITH A THIRD PARTY. Alliance shall also have the right to
control settlement of such action; provided, however, that no settlement shall
be entered into without the written consent of the Schering (which consent shall
not be unreasonably withheld) if such settlement would materially and adversely
affect the interests of Schering.
SECTION 8.05. DEFENSE AND SETTLEMENT OF THIRD PARTY CLAIMS. If a Third
Party asserts that a patent, trademark or other intangible right owned by it is
infringed by any Product, Alliance will be solely responsible for defending
against any such assertions at its cost and expense (subject to the provisions
of Section 8.04(b)). Any determination regarding the necessity to license or
otherwise obtain rights under or invalidate certain Third Party Patents covering
the Product shall be made by Alliance; provided, however, that no settlement may
be entered into without the written consent of Schering (which shall not be
unreasonably withheld) if such settlement would materially and adversely affect
the interests of Schering.*
SECTION 8.06. PATENT EXPENSES. All worldwide Patent Expenses shall be
borne by Alliance, subject to the terms of this Agreement.
SECTION 8.07. TRADEMARKS.
(a) SCHERING. Schering shall be responsible for the selection,
registration and maintenance of all trademarks which it employs in connection
with the Product and shall own and control such trademarks (and pay any costs in
connection therewith). Alliance recognizes the exclusive ownership by Schering
of any proprietary Schering name, logotype or trademark furnished by Schering
(including Schering's Affiliates) for use in connection with the Product.
Alliance shall not, either while this Agreement is in effect, or at any time
thereafter, register, use or attempt to obtain any right in or to any such name,
logotype or trademark or in and to any name, logotype or trademark confusingly
similar thereto.
(b) ALLIANCE. Schering hereby reconveys to Alliance all rights to the
trademark for "Imagent" granted pursuant to the Original
License Agreement.
ARTICLE IX
REPRESENTATIONS AND WARRANTIES
SECTION 9.01. REPRESENTATIONS AND WARRANTIES.
(a) Each of the Parties hereby represents and warrants to the other Party
as follows:
23
(i) This Agreement is a legal and valid obligation binding upon such
Party and enforceable in accordance with its terms. The execution, delivery
and performance of the Agreement by such Party does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a
party or by which it is bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over
it.
(ii) Alliance has not, and during the term of the Agreement neither
Party will, (x) grant any right to any Third Party relating to the Alliance
Patents and to Alliance Know-How in the Field which would conflict with the
rights granted to either Party hereunder, and (y) to the best of its knowledge
neither party is employing (as an employee or consultant), nor will either
Party employ during the term of this Agreement, any person that has been
debarred by the FDA.
(iii) To the best of its knowledge Alliance is not obligated under any
agreement as of the Effective Date and the Restatement Date to pay any Third
Party royalties with respect to the Product. As of the Effective Date and the
Restatement Date there are no such agreements in place.
(b) Alliance hereby represents and warrants to Schering as follows:
(i) It has given Schering access to all its pre-clinical and
clinical records regarding the Product in existence as of the Effective Date
and the Restatement Date.
(ii) As of the Effective Date and the Restatement Date, except as it
may have previously disclosed to Schering in writing or otherwise, it has not
received any notices of infringement or any written communications relating in
any way to a possible infringement with respect to any Alliance Patent.
SECTION 9.02. PERFORMANCE BY AFFILIATES. The Parties recognize that each
Party may perform some or all of its obligations under this Agreement through
Affiliates; provided, however, that each Party shall remain responsible for and
be a guarantor of the performance by its Affiliates and shall cause its
Affiliates to comply with the provisions of this Agreement in connection with
such performance.
ARTICLE X
INFORMATION AND REPORTS
SECTION 10.01. INFORMATION AND REPORTS DURING DEVELOPMENT AND
COMMERCIALIZATION. Schering and Alliance will disclose and make available
(subject to any confidentiality agreements or requirements of law) to each other
without charge all preclinical, clinical, regulatory, pricing, sales and other
Information, including copies of all preclinical and clinical reports, known by
Schering or Alliance directly concerning the Product within the Field at any
time during the term of this Agreement. Each Party shall own and maintain its
own database of clinical trial data accumulated from all clinical trials of the
Product for which it was
24
responsible and of adverse drug event information for the Product. At the option
of the requesting Party, such data shall be provided in a computer readable
format by the providing Party, to the extent available, which shall also assist
in the transfer and validation of such data to the receiving Party. Without
limitation of the foregoing, each Party shall supply to the other the
Information required by the other Party and requested by it (either as a routine
practice or as a specific request) for purposes of compliance with regulatory
requirements.
SECTION 10.02. ADVERSE DRUG EXPERIENCES.
(a) Alliance agrees to provide to Schering for initial and/or periodic
submission to government agencies significant information on the Product from
preclinical laboratory, animal toxicology and pharmacology studies, as well as
adverse drug experience reports from clinical trials and commercial experiences
with the Product;
(b) Each party agrees to, in connection with investigational Products,
report to the other party as soon as possible (and, in any event, within three
(3) days) the receipt of a report of any unexpected or serious experience, if
required for the other Party to comply with regulatory requirements;
(c) Each Party agrees to, in connection with marketed Products, report to
the other Party within three (3) business days of the receipt of a report of any
adverse experience that is serious and unexpected or sooner if required for the
other Party to comply with regulatory requirements. Serious adverse experience
means any experience that suggests a significant hazard, contraindication, side
effect or precaution, or any experience that is fatal or life threatening, is
permanently disabling, requires or prolongs inpatient hospitalization, or is a
congenital anomaly, cancer, or overdose. An unexpected adverse experience is one
not identified in nature, specificity, severity or frequency in the current
investigator brochure or the U.S. labeling for the drug; and
(d) If requested by Schering, Alliance agrees to enter into a standard
operating procedure by and between the Parties to govern the exchange of
information relating to adverse drug experiences and product quality.
SECTION 10.03. RECORDS OF REVENUES AND EXPENSES.
(a) Each Party will maintain complete and accurate records which are
relevant to revenues, costs, expenses and payments on a country-by-country basis
under this Agreement and such records shall be open during reasonable business
hours for a period of two (2) years from creation of individual records for
examination at the other Party's expense and not more often than once each year
by a certified public accountant selected by the other Party, or the other
Party's internal accountants unless the first Party objects to the use of such
internal accountants, for the sole purpose of verifying for the inspecting Party
the correctness of calculations and classifications of such revenues, costs,
expenses or payments made under this Agreement. Each party shall bear its own
costs related to such audit; provided, however, that, for any underpayments by a
Party greater than five percent (5%), such Party shall pay the other Party the
amount of underpayment, interest as provided for in Section 5.04(b) from the
time the
25
amount was due and the other Party's out-of-pocket expenses. For any
underpayments less than five percent (5%) by a Party found under this Section,
such Party shall pay the other Party the amount of underpayment. Any
overpayments by a Party will be refunded to such Party or credited to future
royalties, at such Party's election. Any records or accounting information
received from the other Party shall be Confidential Information for purposes of
Article VII. Results of any such audit shall be provided to both Parties,
subject to Article VII.
(b) If there is a dispute between the Parties following any audit
performed pursuant to Section 10.03(a), either party may refer the issue (an
"AUDIT DISAGREEMENT") to an independent certified public accountant for
resolution. In the event an Audit Disagreement is submitted for resolution by
either Party, the Parties shall comply with the following procedures:
(i) The Party submitting the Audit Disagreement for resolution shall
provide written notice to the other Party that it is invoking the procedures
of this Section 10.03(b).
(ii) Within thirty (30) business days of the giving of such notice,
the Parties shall jointly select a recognized international accounting firm to
act as an independent expert to resolve such Audit Disagreement.
(iii) The Audit Disagreement submitted for resolution shall be
described by the Parties to the independent expert, which description may be
in written or oral form, within ten (10) business days of the selection of
such independent expert.
(iv) The independent expert shall render a decision on the matter as
soon as practicable.
(v) The decision of the independent expert shall be final and
binding unless such Audit Disagreement involves alleged fraud, breach of this
Agreement or construction or interpretation of any of the terms and conditions
hereof.
(vi) All fees and expenses of the independent expert, including any
third party support staff or other costs incurred with respect to carrying out
the procedures specified at the direction of the independent expert in
connection with such Audit Disagreement, shall be borne by the Party that did
not submit the Audit Disagreement in the event that a discrepancy of more than
two percent (2%) results from such decision, and by each Party in inverse
proportion to the disputed amounts awarded to the Party by the independent
expert through such decision (e.g. Alliance disputes $100, the independent
expert awards Alliance $50, then each party pays one-half (1/2) of the
independent expert's costs) in all other cases.
SECTION 10.04. APPLICABILITY. This Article X shall be applicable following
the Restatement Date (without prejudice to any rights accruing prior to the
Restatement Date) only if Schering undertakes Development or Commercialization
activities with regard to a Product following the Restatement Date or exercises
its option under Section 4.01(d).
26
ARTICLE XI
TERM AND TERMINATION
SECTION 11.01. TERM. This Agreement shall commence as of the Effective Date
and, unless sooner terminated as provided herein shall continue in effect until
no royalties or other payments are payable hereunder to either Alliance or
Schering.
SECTION 11.02. TERMINATION.
(a) Notwithstanding any other provision herein, Schering may, prior to
Regulatory Approval of a Product, terminate this Agreement on a country by
country basis or in its entirety upon one (1) month written notice to Alliance.
After receipt of Regulatory Approval of a Product and prior to the First
Commercial Sale of said Product in the applicable country, Schering may
terminate this Agreement on a country by country basis upon two (2) months
written notice to Alliance. After the First Commercial Sale of a Product,
Schering may terminate this Agreement on a country by country basis upon three
(3) months written notice to Alliance.
(b) Failure by Schering or Alliance to comply with any of the respective
material obligations and conditions contained in this Agreement shall entitle
the other Party to give the Party in default notice requiring it to cure such
default. If such default is not cured within ninety (90) days after receipt of
such notice, the notifying Party shall be entitled (without prejudice to any of
its other rights conferred on it by this Agreement) to terminate this Agreement
or in the event of an uncured material breach by Alliance, effect the rights of
Schering set forth in Section 11.02(e) by giving a notice to take effect
immediately. Notwithstanding the foregoing, in the event of a non-monetary
default, if the default is not reasonably capable of being cured within the
ninety (90) day cure period by the defaulting Party and such defaulting Party is
making a good faith effort to cure such default, the notifying Party may not
terminate this Agreement, provided however, that the notifying Party may
terminate this Agreement if such default is not cured within one hundred eighty
(180) days of such original notice of default. The right of either Party to
terminate this Agreement as hereinabove provided shall not be affected in any
way by its waiver of, or failure to take action with respect to any previous
default.
(c) In the event that one of the Parties hereto shall go into liquidation,
a receiver or a trustee be appointed for the property or estate of that Party
and said receiver or trustee is not removed within sixty (60) days, or the Party
makes an assignment for the benefit of creditors (collectively, a "BANKRUPTCY
EVENT"), and whether any of the aforesaid Bankruptcy Events be the outcome of
the voluntary act of that Party, or otherwise, the other Party shall be entitled
to terminate this Agreement (or in the event Alliance suffers such a Bankruptcy
Event, Schering may effect its rights described in Section 11.02(e) forthwith by
giving a written notice to Alliance.
(d) In the event that this Agreement is terminated by Schering in one or
more countries or in its entirety, and in the event that the Agreement is
terminated by either Party in its entirety in accordance with Sections 11.02(a),
(b) or (c) hereof, Schering will with respect to each country for which the
termination applies entirely:
27
(i) deliver to Alliance the Alliance Know-How and assign to Alliance
its rights in said Alliance Know-How and Alliance Patents if any, in either
case relating solely to the country that is the subject of the termination;
(ii) not use the Alliance Know-How as long as it has to be kept
confidential pursuant to Article VII hereof in such country;
(iii) not infringe any of the Alliance Patents in such country;
(iv) make all payments accrued under this Agreement with respect to
such country prior to the effective termination date;
(v) transfer all regulatory filings and approvals related to the
Product in such country to Alliance upon Alliance's written request for same;
(vi) transfer to Alliance responsibility for and control of ongoing
work of Schering related to the Product, Affiliates and Third Parties in an
expeditious and orderly manner with the costs for such work assumed by
Alliance as of the date of notice; and
(vii) sell to Alliance, at any time within ninety (90) days of such
termination, at Alliance's election, all or any portion of the inventory of
the Product owned by Schering or its Affiliates which are intended for sale in
such country at a price equal to Schering's or its Affiliate's cost for such
inventory. Such election shall be made by Alliance in writing and within
thirty (30) days of such election, Schering shall ship at Alliance's cost and
direction such inventory to Alliance. Alliance shall pay for such inventory
within forty-five (45) days of receipt of such inventory.
(e) In the event of a Bankruptcy Event or a material default described in
Sections 11.02(b) and (c) by Alliance (which default is not cured as provided
therein), Schering may elect in lieu of terminating this Agreement to declare
the license granted pursuant to this Agreement to be irrevocable. From the date
of receipt of notice of such election, Alliance shall have no further rights or
obligations under this Agreement, except that Alliance may enforce any financial
obligations of Schering, including those arising under Article V herein before
or after such election, and Schering may enforce any manufacturing and supply
obligations of Alliance, including those arising under Section 11.02(f);
provided, however, that if such election occurs prior to the First Commercial
Sale of the Product, any additional Development Expenses and reasonable costs
incurred by Schering to Commercialize the Product as a result of such election
shall be credited against amounts payable by Schering to Alliance.
(f) In the event of termination of this Agreement pursuant to this Section
11.02 where the Party terminating this Agreement is the Manufacturing Party, the
Manufacturing Party shall continue to provide for manufacture of the Product to
the extent provided prior to notice of such termination, from the effective date
of such termination until such time as the Non-Manufacturing Party is able to
secure an equivalent alternative commercial manufacturing source, as requested
by the Non-Manufacturing Party.
28
(g) Except where expressly provided for otherwise in this Agreement,
termination of this Agreement shall not relieve the Parties hereto of any
liability, including any obligation to make payments hereunder, which accrued
hereunder prior to the effective date of such termination, nor preclude any
Party from pursuing all rights and remedies it may have hereunder or at law or
in equity with respect to any breach of this Agreement nor prejudice any Party's
right to obtain performance of any obligation.
SECTION 11.03. SURVIVING RIGHTS. The rights and obligations set forth in
this Agreement shall extend beyond the term or termination of the Agreement only
to the extent expressly provided for herein, or the extent that the survival of
such rights or obligations are necessary to permit their complete fulfillment or
discharge.
ARTICLE XII
INDEMNIFICATION
SECTION 12.01. INDEMNIFICATION. With respect to the Product (determined on
a country by country basis):
(a) Schering and Alliance hereby agree to save, defend and hold the other
Party and its agents and employees harmless from and against any and all suits,
claims, actions, demands, liabilities, expenses and/or losses, including
reasonable legal expenses and attorneys' fees (collectively, "LOSSES") resulting
directly from the Development or Commercialization of the Product to the extent
such Development or Commercialization was performed by such Party except to the
extent such Losses result from the negligence or willful misconduct of the other
Party, in which case such Party hereby agrees to save, defend and hold the other
Party and its agents and employees harmless from any and all such Losses.
(b) Each indemnified Party agrees to give the indemnifying Party prompt
written notice of any Loss or discovery of fact upon which such indemnified
Party intends to base a request for indemnification under Sections 12.01(a).
Each Party shall furnish promptly to the other copies of all papers and official
documents received in respect of any Loss. With respect to any Loss relating
solely to the payment of money damages and which will not result in the
indemnified Party becoming subject to injunctive or other relief or otherwise
adversely affecting the business of the indemnified Party in any manner, and as
to which the indemnifying Party shall have acknowledged in writing the
obligation to indemnify the indemnified Party hereunder, the indemnifying Party
shall have the sole right to defend, settle or otherwise dispose of such Loss,
on such terms as the indemnifying Party, in its sole discretion, shall deem
appropriate. The indemnifying Party shall obtain the written consent of the
indemnified Party, which shall not be unreasonably withheld or delayed, prior to
ceasing to defend, settling or otherwise disposing of any Loss if as a result
thereof the indemnified Party would become subject to injunctive or other
equitable relief or any remedy other than the payment of money, which payment
would be the responsibility of the indemnifying Party. The indemnifying Party
shall not be liable for any settlement or other disposition of a Loss by the
indemnified Party which is reached without the written consent of the
indemnifying Party. The reasonable costs and expenses, including reasonable fees
and disbursements of counsel incurred by any
29
indemnified Party in connection with any Loss, shall be reimbursed on a
quarterly basis by the indemnifying Party, without prejudice to the indemnifying
Party's right to contest the indemnified Party's right to indemnification and
subject to refund in the event the indemnifying party is ultimately held not to
be obligated to indemnify the indemnified Party.
ARTICLE XIII
MISCELLANEOUS
SECTION 13.01. ASSIGNMENT.
(a) Schering may assign any of its rights or obligations under this
Agreement in any country to any of its Affiliates or to any sublicensee as
provided in Section 3.01; provided, however, that such assignment shall not
relieve Schering of its responsibilities for performance of its obligations
under this Agreement.
(b) Alliance may assign any of its rights or obligations under this
Agreement in any country to any of its Affiliates or to any sublicensee if
permitted by Section 3.02; provided, however, that such assignment shall not
relieve Alliance of its responsibilities for performance of its obligations
under this Agreement.
(c) Either Party may assign its rights or obligations under this Agreement
in connection with a merger or similar reorganization or the sale of all or
substantially all of its assets, or otherwise with the prior written consent of
the other Party. This Agreement shall survive any such merger or reorganization
of either Party with or into, or such sale of assets to, another Party and no
consent for such merger, reorganization or sale shall be required hereunder;
provided, that in the event of such merger, reorganization or sale, no
intellectual property rights of the acquiring corporation shall be included in
the technology licensed hereunder.
(d) This Agreement shall be binding upon and inure to the benefit of the
successors and permitted assigns of the Parties. Any assignment not in
accordance with this Agreement shall be void.
SECTION 13.02. RETAINED RIGHTS. Nothing in this Agreement shall limit in
any respect the right of either Party to conduct research and development and to
market products using such Party's technology other than as herein expressly
provided.
SECTION 13.03. FORCE MAJEURE. Neither Party shall lose any rights hereunder
or be liable to the other Party for damages or losses on account of failure of
performance by the defaulting Party if the failure is occasioned by government
action, war, fire, explosion, flood, strike, lockout, embargo, act of God, or
any other cause beyond the control of the defaulting Party, provided that the
Party claiming force majeure has extended all reasonable efforts to avoid or
remedy such force majeure, continues to employ such efforts and promptly
notifies the other Party of such force majeure event.
30
SECTION 13.04. FURTHER ACTIONS. Each Party agrees to execute, acknowledge
and deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.
SECTION 13.05. NO TRADEMARK RIGHTS. Except as otherwise provided herein,
no right, express or implied, is granted by the Agreement to use in any manner
the name "Schering," or any other trade name or trademark of the other Party or
its Affiliates in connection with the performance of the Agreement.
ARTICLE 13.06. NOTICES. All notices hereunder shall be in writing and
shall be deemed given if delivered personally, mailed by registered or certified
mail (return receipt requested), postage prepaid, or sent by express courier
service, to the Parties at the following addresses (or at such other address for
a Party as shall be specified by like notice; provided, however, that notices of
a change of address shall be effective only upon receipt thereof).
(a) If to Alliance:
Alliance Pharmaceutical Corp.
▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: President
Telecopy: (▇▇▇) ▇▇▇-▇▇▇▇
With a copy to:
Stroock & Stroock & ▇▇▇▇▇ LLP
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Telecopy: (▇▇▇) ▇▇▇-▇▇▇▇
(b) If to Schering:
▇▇▇▇▇▇▇▇ ▇▇
▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇
Attention: Legal Department
Telecopy: ▇▇▇▇-▇▇-▇▇▇▇ 4086
With a copy to:
▇▇▇▇▇▇▇▇ ▇▇
▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇
Attention: SBU Diagnostics & Radiopharmaceuticals
Telecopy: ▇▇▇▇-▇▇-▇▇▇▇ 6736
31
SECTION 13.07. WAIVER. Except as specifically provided for herein, the
waiver from time to time by either of the Parties of any of their rights or
their failure to exercise any remedy shall not operate or be construed as a
continuing waiver of same or any other of such Party's rights or remedies
provided in this Agreement.
SECTION 13.08. SEVERABILITY. If any term, covenant or condition of this
Agreement or the application thereof to any Party or circumstances shall, to any
extent or in any country, be held to be invalid or unenforceable, then (i) the
remainder of this Agreement, or the application of such term, covenant or
condition to Parties or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant
or condition of this Agreement shall be valid and be enforced to the fullest
extent permitted by law; and (ii) the Parties hereto covenant and agree to
renegotiate any such term, covenant or application thereof in good faith in
order to provide a reasonably acceptable alternative to the term, covenant or
condition of this Agreement or the application thereof that is invalid or
unenforceable, it being the intent of the Parties that the basic purposes of
this Agreement are to be effectuated.
SECTION 13.09. AMBIGUITIES. Ambiguities, if any, in this Agreement shall
not be construed against any Party, irrespective of which Party may be deemed to
have authored the ambiguous provision.
SECTION 13.10. GOVERNING LAW. This Agreement shall be governed by and
interpreted under the laws of the State of
New York as applied to contracts
entered into and performed entirely in
New York by
New York residents.
SECTION 13.11. HEADINGS. The sections and paragraph headings contained
herein are for the purposes of convenience only and are not intended to define
or limit the contents of said sections or paragraphs.
SECTION 13.12. COUNTERPARTS. This Agreement may be executed in one or more
counterparts (and by facsimile), each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.
SECTION 13.13. ENTIRE AGREEMENT; AMENDMENTS. This Agreement, including all
Exhibits attached hereto and thereto, and all documents delivered concurrently
herewith and therewith, set forth all the covenants, promises, agreements,
warranties, representations, conditions and understandings between the Parties
hereto and supersede and terminate all prior agreements and understandings
between the Parties. There are no covenants, promises, agreements, warranties,
representations, conditions or understandings, either oral or written, between
the Parties other than as set forth herein and therein. No subsequent
alteration, amendment, change or addition to this Agreement shall be binding
upon the Parties hereto unless reduced to writing and signed by the respective
authorized officers of the Parties. This Agreement, including without limitation
the exhibits, schedules and attachments thereto, are intended to define the full
extent of the legally enforceable undertakings of the Parties hereto,
32
and no promise or representation, written or oral, which is not set forth
explicitly is intended by either party to be legally binding. Both Parties
acknowledge that in deciding to enter into the Agreement and to consummate the
transaction contemplated thereby neither has relied upon any statement or
representations, written or oral, other than those explicitly set forth therein.
SECTION 13.14. EXPENSES. Except as otherwise specified in this Agreement,
all costs and expenses, including, without limitation, fees and disbursements of
counsel, financial advisors and accountants, incurred in connection with this
Agreement and the transactions contemplated hereby shall be paid by the Party
incurring such costs and expenses.
SECTION 13.15. INDEPENDENT CONTRACTORS. The status of the Parties under
this Agreement shall be that of independent contractors. Neither Party shall
have the right to enter into any agreements on behalf of the other Party, nor
shall it represent to any person that it has any such right or authority.
Nothing in this Agreement shall be construed as establishing a partnership or
joint venture relationship between the Parties.
SECTION 13.16. USE OF NAMES. Neither Party shall use the name of the other
Party in relation to this transaction in any public announcement, press release
or other public document without the written consent of such other Party, which
consent shall not be unreasonably withheld or delayed; provided, however, that
either Party may use the name of the other Party in any document filed with any
regulatory agency or authority, including the FDA and the Securities and
Exchange Commission, in which case Schering shall be referred to as "Schering
AG, Germany". Alliance agrees not to use the name "Schering" in relation to this
transaction in any press release, public announcement or other public document
without the approval of Schering, which approval shall not be unreasonably
withheld or delayed.
IN WITNESS WHEREOF, Alliance and Schering have caused this Agreement to be
executed as of the date first written above by their respective officers
thereunto duly authorized.
ALLIANCE PHARMACEUTICAL CORP
By:
----------------------------
Name:
Title:
SCHERING AKTIENGESELLSCHAFT
By:
----------------------------
Name: ▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇
Title: Head of SBU DG & RP
33
By:
---------------------------
Name: ▇▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: Licensing and Cooperations
DG & RP
34
EXHIBIT A
DETERMINATION OF CERTAIN ACCOUNTING TERMS
As a supplement to the definitions provided in Article I of the License
Agreement (this "AGREEMENT"), originally dated as of September 23, 1997, and
amended and restated in its entirety as of February 22, 2002 between
ALLIANCE
PHARMACEUTICAL CORP. and SCHERING AKTIENGESELLSCHAFT, the following accounting
terms shall be further specified as follows, with the intent that the following
terms are to be interpreted in accordance with their reasonable and customary
meaning within the industry and consistently applied by a Party on a
company-wide basis:
1. COST OF GOODS
Cost of Goods shall be equal to the sum of Material Costs, Direct Labor
costs and Indirect Costs.
A. "MATERIAL COSTS" shall mean the prices paid for raw material
components and purchased finished goods, including any packaging necessary for
the shipment of products, which are purchased from outside vendors as well as
any freight and duty where applicable.
B. "DIRECT LABOR COSTS" shall mean the labor hours required for an
operation for such a Product multiplied by the direct labor rate for work
centers within the relevant manufacturing operating unit (including salaries,
wages and benefits).
C. "INDIRECT COSTS" shall mean other costs associated with the
operating unit(s) manufacturing a Product; provided, however, overhead
attributable to unrelated facilities, or parts thereof, shall be excluded and
that such Indirect Costs shall exclude costs associated with unused
manufacturing capacity. Indirect Costs shall include expenses associated with
quality assurance, manufacturing and engineering associated with the operating
unit(s) manufacturing a Product and shall include straight line depreciation
and property taxes specifically associated with the plant(s) manufacturing a
Product.
A-1
EXHIBIT B
ALLIANCE PATENTS
--------------------------------
PATENT NUMBER
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
B-1
EXHIBIT C
ALLIANCE HI PATENTS
--------------------------------
PATENT NUMBER
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
*
--------------------------------
C-1
EXHIBIT D
SCHERING HI PATENTS
----------------------- -----------------------
INT. NO. INT. NO.
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
*
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
* *
----------------------- -----------------------
*
----------------------- -----------------------
*
----------------------- -----------------------
* *
----------------------- -----------------------
*
----------------------- -----------------------
D-1
